在使用0.1%阿达帕林凝胶进行维持治疗期间对微粉刺形成的控制。

Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%.

作者信息

Thielitz A, Sidou F, Gollnick H

机构信息

Department of Dermatology and Venereology, Medical Faculty, Otto von Guericke Universität Magdeburg, Germany.

出版信息

J Eur Acad Dermatol Venereol. 2007 Jul;21(6):747-53. doi: 10.1111/j.1468-3083.2007.02190.x.

DOI:10.1111/j.1468-3083.2007.02190.x

PMID:17567301

Abstract

BACKGROUND

Microcomedones representing the clinically non-visible central precursor lesions of acne are induced by sebaceous hyperplasia as well as altered follicular growth and differentiation, and evolve into both comedones and inflammatory lesions. Thus, targeting microcomedone formation is essential in the prevention and therapeutic control of acne.

OBJECTIVE

The aim of this study was to assess the capacity of adapalene gel, 0.1%, to control the number of microcomedones after a combination treatment followed by a maintenance treatment.

METHODS

This was a single-site exploratory study in subjects with a diagnosis of mild to moderate acne vulgaris and the presence of at least 250 microcomedones per cm(2) at screening visit, counted via cyanoacrylate strips (CyASt). During the first 8 weeks, a combination of adapalene gel (0.1%) and benzoyl peroxide gel (2.5%) was applied. During the randomized, investigator-blinded, and vehicle-controlled 12-week maintenance phase, adapalene once daily (QD), or adapalene alternately with its vehicle once daily every other day (QoD), or vehicle QD were applied to the face. CyASt sampling on the forehead was done at baseline, week 8, and week 20. Lesion counting allowing calculating a defined success rate was done at all visits.

RESULTS

A total of 54 subjects entered the combination phase, and 49 subjects were randomized into the maintenance phase: 16 in both the adapalene QD and the QoD group and 17 subjects receiving the vehicle. The microcomedone median count decreased for all groups until week 8 (end of combination phase) from 319 to 157. Microcomedone counts at the end of the maintenance phase (week 20) showed a significant percent difference (P = 0.04) between adapalene QoD (-53.5) and the vehicle (-42.1) and between adapalene QD (-50.6) and the vehicle (P = 0.037) compared with baseline.

CONCLUSION

The application of adapalene gel, 0.1% monotherapy daily, or alternately every other day, significantly helps to control the microcomedone count during a 12-week maintenance treatment after a previous combination therapy with benzoyl peroxide in patients with mild to moderate acne.

摘要

背景

微粉刺是痤疮临床上不可见的中央前体病变，由皮脂腺增生以及毛囊生长和分化改变引起，并演变为粉刺和炎性病变。因此，针对微粉刺的形成对于痤疮的预防和治疗控制至关重要。

目的

本研究的目的是评估0.1%阿达帕林凝胶在联合治疗后进行维持治疗时控制微粉刺数量的能力。

方法

这是一项单中心探索性研究，研究对象为诊断为轻度至中度寻常痤疮且在筛查访视时每平方厘米至少有250个微粉刺的患者，通过氰基丙烯酸酯条（CyASt）计数。在最初的8周内，联合应用阿达帕林凝胶（0.1%）和过氧化苯甲酰凝胶（2.5%）。在随机、研究者设盲且以赋形剂为对照的12周维持阶段，将阿达帕林每日一次（QD），或阿达帕林与赋形剂隔日交替每日一次（QoD），或赋形剂每日一次应用于面部。在基线、第8周和第20周对前额进行CyASt采样。在所有访视时进行皮损计数以计算明确的成功率。

结果

共有54名受试者进入联合治疗阶段，49名受试者被随机分为维持治疗阶段：阿达帕林QD组和QoD组各16名，17名受试者接受赋形剂治疗。所有组的微粉刺中位数计数在第8周（联合治疗阶段结束）前均从319降至157。与基线相比，维持治疗阶段结束时（第20周），阿达帕林QoD组（-53.5）与赋形剂组（-42.1）之间以及阿达帕林QD组（-50.6）与赋形剂组之间的微粉刺计数显示出显著的百分比差异（P = 0.04）（P = 0.037）。